search

Active clinical trials for "Angioedema"

Results 1-10 of 171

Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients...

Hereditary Angioedema

The first-in-human Phase 1 study will evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ADX-324 in healthy volunteers (HV) and in patients with Hereditary Angioedema (HAE).

Recruiting41 enrollment criteria

NTLA-2002 in Adults With Hereditary Angioedema (HAE)

Hereditary Angioedema

This study will be conducted to evaluate the safety, tolerability, activity, pharmacokinetics, and pharmacodynamics of NTLA-2002 in adults with Hereditary Angioedema (HAE).

Recruiting11 enrollment criteria

COrticosteroids in acUte uRticAria in emerGency dEpartment

UrticariaAngiœdema

To demonstrate the non-inferiority of the efficacy of a single antihistamine in comparison with an association of antihistamine and corticosteroid in the treatment of acute urticaria in emergency departments

Recruiting27 enrollment criteria

A Gene Therapy Study of BMN 331 in Subjects With Hereditary Angioedema

Hereditary AngioedemaHAE

This is a Phase 1/2, single-arm, open-label, dose-escalation and dose-expansion study of BMN 331 for the treatment of hereditary angioedema (HAE) due to C1 Esterase Inhibitor (C1-INH) protein deficiency. The study drug BMN 331is identified as AAV5 hSERPING1, an adeno-associated virus (AAV5)-based gene therapy vector that expresses wild-type human C1 Esterase Inhibitor (hC1-INH), under the control of a liver-selective promoter, and is being developed for the treatment of HAE with C1-INH deficiency. The pharmaceutical form of BMN 331 is a solution for intravenous infusion.

Recruiting12 enrollment criteria

Study Evaluating the Efficacy and Safety of Povorcitinib in Adults With Chronic Spontaneous Urticaria...

UrticariaChronic Spontaneous Urticaria4 more

This study is being conducted to evaluate the efficacy and safety of povorcitinib in adults with CSU that is inadequately controlled using SOC treatments.

Recruiting15 enrollment criteria

Berotralstat Treatment in Children With Hereditary Angioedema

Hereditary AngioedemaPediatric

The purpose of this study is to evaluate the pharmacokinetics (PK) and safety of berotralstat to determine the appropriate weight-based dose for pediatric participants 2 to < 12 years old for prophylactic treatment to prevent attacks of hereditary angioedema (HAE).

Recruiting10 enrollment criteria

A Study of Lanadelumab (SHP643) in Chinese Participants With Hereditary Angioedema (HAE)

Hereditary Angioedema (HAE)

The main aim of this study is to evaluate the safety of lanadelumab in Chinese participants with HAE. Participants will be treated with lanadelumab for 26 weeks.

Recruiting24 enrollment criteria

A Study of STAR-0215 in Participants With Hereditary Angioedema

Hereditary Angioedema

The goal of this clinical trial is to test the drug STAR-0215 in participants with hereditary angioedema (HAE). One group of participants will get 1 dose of STAR-0215, and two other groups will get 2 doses of STAR-0215. Researchers will study the effects of STAR-0215 in participants with HAE as this is the first time that the drug has been given to participants with HAE.

Recruiting10 enrollment criteria

CSL312_3003 Safety and Pharmacokinetic Study in Subjects 2 to 11 Years of Age With Hereditary Angioedema...

Hereditary Angioedema (HAE)

The purpose of this study is to investigate the safety, PK / PD, and efficacy of SC CSL312 for prophylactic treatment of pediatric subjects with HAE.

Recruiting8 enrollment criteria

An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 for On-Demand Treatment...

Hereditary Angioedema

This is an open-label, multicenter extension trial to evaluate the long-term safety of KVD900 in patients who are 12 years or older with HAE type I or II.

Recruiting29 enrollment criteria
12...18

Need Help? Contact our team!


We'll reach out to this number within 24 hrs